In vivo visualizing the IFN-β response required for tumor growth control in a therapeutic model of polyadenylic-polyuridylic acid administration

Journal of Immunology

Volumn 196, Issue 6, 2016, Pages 2860-2869

  Nocera, David Andrés ^a   Roselli, Emiliano ^a   Araya, Paula ^a   Nuñez, Nicolás Gonzalo ^a,b   Lienenklaus, Stefan ^c   Jablonska, Jadwiga ^c   Weiss, Siegfried ^c   Gatti, Gerardo ^a,d   Brinkmann, Melanie M ^c   Kröger, Andrea ^c,e   Morón, Gabriel ^a   Maccioni, Mariana ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b PSL RESEARCH UNIVERSITY   (France)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d 9 de Julio 941   (Argentina)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD11B ANTIGEN; GLYCOPROTEIN P 15095; INTERFERON REGULATORY FACTOR 3; POLYADENYLIC POLYURIDYLIC ACID; CARRIER PROTEIN; TOLL LIKE RECEPTOR 3; UNC93B1 PROTEIN, MOUSE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GROWTH REGULATION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOSURVEILLANCE; IN VIVO STUDY; INNATE IMMUNITY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOGENESIS; EXPERIMENTAL MELANOMA; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; NUDE MOUSE; PROCEDURES;

ANIMALS; ANTIGENS, CD11C; CARCINOGENESIS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; MELANOMA, EXPERIMENTAL; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; POLY A-U; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 84962595348     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501044     Document Type: Article

References (50)

1. U'Ren, L., A. Guth, D. Kamstock, and S. Dow. 2010. Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol. Immunother. 59:587-598.
2. Jablonska, J., S. Leschner, K. Westphal, S. Lienenklaus, and S. Weiss. 2010. Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 120:1151-1164.
3. Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, et al. 2011. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208:1989-2003.
4. + T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208:2005-2016.
5. Bidwell, B. N., C. Y. Slaney, N. P. Withana, S. Forster, Y. Cao, S. Loi, D. Andrews, T. Mikeska, N. E. Mangan, S. A. Samarajiwa, et al. 2012. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18:1224-1231.
6. Wu, C. F., L. Andzinski, N. Kasnitz, A. Kröger, F. Klawonn, S. Lienenklaus, S. Weiss, and J. Jablonska. 2015. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int. J. Cancer 137:837-847.
7. Kawai, T., and S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21:317-337.
8. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373-384.
9. Currie, A. J., R. G. Van Der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. Robinson. 2008. Targeting the effector site with IFN-alphabetainducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 180:1535-1544.
10. Swann, J. B., Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth. 2007. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178:7540-7549.
11. Perrot, I., F. Deauvieau, C. Massacrier, N. Hughes, P. Garrone, I. Durand, O. Demaria, N. Viaud, L. Gauthier, M. Blery, et al. 2010. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J. Immunol. 185:2080-2088.
12. Aranda, F., E. Vacchelli, F. Obrist, A. Eggermont, J. Galon, C. Sautès-Fridman, I. Cremer, J. Henrik Ter Meulen, L. Zitvogel, G. Kroemer, and L. Galluzzi. 2014. Trial watch: Toll-like receptor agonists in oncological indications. OncoImmunology 3:e29179.
13. Galluzzi, L., E. Vacchelli, A. Eggermont, W. H. Fridman, J. Galon, C. Sautès-Fridman, E. Tartour, L. Zitvogel, and G. Kroemer. 2012. Trial watch: experimental Toll-like receptor agonists for cancer therapy. OncoImmunology 1:699-716.
14. Nicodemus, C. F., and J. S. Berek. 2010. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2:137-140.
15. Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Y. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, and M. K. Gately. 1996. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4:471-481.
16. Lienenklaus, S., M. Cornitescu, N. Zietara, M. Łyszkiewicz, N. Gekara, J. Jabłónska, F. Edenhofer, K. Rajewsky, D. Bruder, M. Hafner, et al. 2009. Novel reporter mouse reveals constitutive and inflammatory expression of IFNbeta in vivo. J. Immunol. 183:3229-3236.
17. Solodova, E., J. Jablonska, S. Weiss, and S. Lienenklaus. 2011. Production of IFN-β during Listeria monocytogenes infection is restricted to monocyte/macrophage lineage. PLoS One 6:e18543. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018543.
18. Andreani, V., G. Gatti, L. Simonella, V. Rivero, and M. Maccioni. 2007. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res. 67:10519-10527.
19. Núñez, N. G., V. Andreani, M. I. Crespo, D. A. Nocera, M. L. Breser, G. Morón, L. Dejager, C. Libert, V. Rivero, and M. Maccioni. 2012. IFNb produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 72:592-603.
20. Gatti, G., N. G. Nuñez, D. A. Nocera, L. Dejager, C. Libert, C. Giraudo, and M. Maccioni. 2013. Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β production capable of improving dendritic cell function. Eur. J. Immunol. 43:1849-1861.
21. Cross, M., and R. Renkawitz. 1990. Repetitive sequence involvement in the duplication and divergence of mouse lysozyme genes. EMBO J. 9:1283-1288.
22. Faust, N., F. Varas, L. M. Kelly, S. Heck, and T. Graf. 2000. Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 96:719-726.
23. Geissmann, F., C. Auffray, R. Palframan, C. Wirrig, A. Ciocca, L. Campisi, E. Narni-Mancinelli, and G. Lauvau. 2008. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol. 86:398-408.
24. Satpathy, A. T., X. Wu, J. C. Albring, and K. M. Murphy. 2012. Re (de) fining the dendritic cell lineage. Nat. Immunol. 13:1145-1154.
25. Kallfass, C., S. Lienenklaus, S. Weiss, and P. Staeheli. 2013. Visualizing the beta interferon response in mice during infection with influenza A viruses expressing or lacking nonstructural protein 1. J. Virol. 87:6925-6930.
26. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by Tolllike receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
27. Perry, A. K., G. Chen, D. Zheng, H. Tang, and G. Cheng. 2005. The host type I interferon response to viral and bacterial infections. Cell Res. 15:407-422.
28. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-a/b gene induction. Immunity 13:539-548.
29. Brinkmann, M. M., E. Spooner, K. Hoebe, B. Beutler, H. L. Ploegh and Y.-M. Kim. 2007. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J. Cell Biol. 177:265-275.
30. Kim, Y.-M., M. M. Brinkmann, M.-E. Paquet, and H. L. Ploegh. 2008. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452:234-238.
31. Blasius, A. L., and B. Beutler. 2010. Intracellular Toll-like receptors. Immunity 32:305-315.
32. Qi, R., D. Singh, and C. C. Kao. 2012. Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization. J. Biol. Chem. 287:32617-32629.
33. Garcia-Cattaneo, A., F.-X. Gobert, M. Müller, F. Toscano, M. Flores, A. Lescure, E. Del Nery, and P. Benaroch. 2012. Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc. Natl. Acad. Sci. USA 109:9053-9058.
34. Huh, J.-W. W., T. Shibata, M. Hwang, E.-H. H. Kwon, M. S. Jang, R. Fukui, A. Kanno, D.-J. J. Jung, M. H. Jang, K. Miyake, and Y.-M. M. Kim. 2014. UNC93B1 is essential for the plasma membrane localization and signaling of Toll-like receptor 5. Proc. Natl. Acad. Sci. USA 111:7072-7077.
35. Salaun, B., L. Zitvogel, C. Asselin-Paturel, Y. Morel, K. Chemin, C. Dubois, C. Massacrier, R. Conforti, M. P. Chenard, J. C. Sabourin, et al. 2011. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71:1607-1614.
36. Wang, B. X., R. Rahbar, and E. N. Fish. 2011. Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 31:545-552.
37. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207:2053-2063.
38. Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E. E. Bates, G. Trinchieri, C. Caux, and P. Garrone. 2005. A type I interferon autocrineparacrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201:1435-1446.
39. Sistigu, A., T. Yamazaki, E. Vacchelli, K. Chaba, D. P. Enot, J. Adam, I. Vitale, A. Goubar, E. E. Baracco, C. Remédios, et al. 2014. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20:1301-1309.
40. Corrales, L., L. H. Glickman, S. M. McWhirter, D. B. Kanne, K. E. Sivick, G. E. Katibah, S.-R. Woo, E. Lemmens, T. Banda, J. J. Leong, et al. 2015. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports 11:1018-1030.
41. Lacour, J., F. Lacour, A. Spira, M. Michelson, J. Y. Petit, G. Delage, D. Sarrazin, G. Contesso, and J. Viguier. 1984. Adjuvant treatment with polyadenylicpolyuridylic acid in operable breast cancer: updated results of a randomised trial. Br. Med. J. (Clin. Res. Ed.) 288:589-592.
42. Laplanche, A., L. Alzieu, T. Delozier, J. Berlie, C. Veyret, P. Fargeot, M. Luboinski, and J. Lacour. 2000. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res. Treat. 64:189-191.
43. Jeung, H.-C., Y. W. Moon, S. Y. Rha, N. C. Yoo, J. K. Roh, S. H. Noh, J. S. Min, B. S. Kim, and H. C. Chung. 2008. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann. Oncol. 19:520-526.
44. Conforti, R., Y. Ma, Y. Morel, C. Paturel, M. Terme, S. Viaud, B. Ryffel, M. Ferrantini, R. Uppaluri, R. Schreiber, et al. 2010. Opposing effects of Toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70:490-500.
45. Sugiyama, T., K. Hoshino, M. Saito, T. Yano, I. Sasaki, C. Yamazaki, S. Akira, and T. Kaisho. 2008. Immunoadjuvant effects of polyadenylic: polyuridylic acids through TLR3 and TLR7. Int. Immunol. 20:1-9.
46. Zhao, G. N., D. S. Jiang, and H. Li. 2015. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim. Biophys. Acta 1852:365-378.
47. Matsumoto, M., M. Tatematsu, F. Nishikawa, M. Azuma, N. Ishii, A. Morii-Sakai, H. Shime, and T. Seya. 2015. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat. Commun. 6:6280.
48. Ivashkiv, L. B., and L. T. Donlin. 2014. Regulation of type I interferon responses. Nat. Rev. Immunol. 14:36-49.
49. Porritt, R. A., and P. J. Hertzog. 2015. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 36:150-160.
50. Agarwal, S. K., M. Wu, C. K. Livingston, D. H. Parks, M. D. Mayes, F. C. Arnett, and F. K. Tan. 2011. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res. Ther. 13:R3.